Skip to main content
. Author manuscript; available in PMC: 2019 Nov 11.
Published in final edited form as: Adv Drug Deliv Rev. 2018 Jul 21;130:113–130. doi: 10.1016/j.addr.2018.07.009

Figure 4.

Figure 4.

(A) Half-life extension mechanisms of dulaglutide. (B) FcRn recycling pathway of dulaglutide. (C) Mean concentration-time profile of dulaglutide following single dose of 1.5 mg subcutaneously injected in abdomen, thigh, or arm. Data obtained from an EMA assessment report of Trulicity® [87].